

The drugs don't work!

Frank O'Riordan Antimicrobial Pharmacist MUH/SIVUH



"The threat of untreatable infections is real. Although previously unthinkable, the day when antibiotics don't work is upon us. We are already seeing germs that are stronger than any antibiotics we have to treat them."

 Arjun Srinivasan, MD, Associate Director for Healthcare Associated Infection Prevention Programs, Division of Healthcare Quality Promotion, US Centres for Disease Control and Prevention

Introduction

- Antibiotic use and resistance
- Consequences of antibiotic resistance-post antibiotic era?
- What can we do about it

Λ	n	+	ıh	110	۱Ŧ۱	CS




- Alexander Fleming's accidental discovery of penicillin
- Average life span USA extended by 10 years
- Common yet frequently deadly illnesses such as pneumonia and tuberculosis (TB) could be treated effectively
- A small cut no longer had the potential to be fatal if it became infected, and the dangers of routine surgery and childbirth were vastly reduced.



"Penicillin should only be used if there is a properly diagnosed reason and, if it needs to be used, use the highest possible dose for the shortest time necessary. Otherwise antibiotic resistance will develop"

Alexander Fleming, 1945

Antibiotic discovery and resistance timeline



Scale of antibiotic use


- 100,000 million kg antibiotics produced since 1941 50% human use
- -80% community
- -20% hospitals

35-50% of hospital patients are prescribed an antibiotic of which 50% could be classed as inappropriate

- 50% agricultural use -20% therapeutic -80% prophylactic/growth promotion



Trend of antimicrobial consumption of
Antibacterials For Systemic Use (ATC group J01) in
the community (primary care sector) in Ireland
from 1998 to 2013








Table 1. Breakdown by pharmacological drug groups for outpatient antibiotic use in Ireland for 2012 and 2013.

	2012	Percent of 2012			Percent Change 2012 to 2013
Penicillins	12.5	54.6%	13.1	55.1%	5.0%
Narrow spectrum penicillins	1.0	4.4%	1.1	4.5%	7.2%
Beta-lactamase resistant penicillins	1.0	4.6%	1.2	5.0%	13.6%
Broad spectrum penicillins	3.7	15.9%	3.9	16.4%	6.8%
Penicillin with beta-lactamase inhibitor	6.8	29.7%	7.0	29.2%	2.4%
Macrolides and related drugs	4.2	18.2%	4.4	18.5%	5.7%
Tetracylines	2.9	12.8%	3.0	12.5%	1.6%
Cephalosporins and other beta-lactam drugs	1.2	5.2%	1.4	5.7%	14.6%
First-generation cephalosporins	0.2	0.8%	0.2	0.8%	10.9%
Second-generation cephalosporins	0.9	4.0%	1.1	4.5%	17.9%
Third-generation cephalosporins	0.1	0.4%	0.1	0.4%	-8.5%
Quinolones	0.9	3.8%	0.9	3.7%	0.3%
Sulfonamides and Trimethoprim	1.2	5.0%	1.0	4.1%	-14.5%
Other antibiotics	0.1	0.5%	0.1	0.4%	-8.1%
TOTAL	22.9	100.0%	23.8	100.0%	4.0%

HPSC



Figure 2. Outpatient antibiotic consumption in Ireland by


HPSC

Antibiotic use in nursing home patients

- \bullet Crude national antimic robial prevalence of 9.8%
- \bullet Indications-Treatment and prophylaxis of infection
- Relevant microbiology specimen obtained for 27% of antibiotic prescriptions with the following isolated
- E.coli 33% (of which 29% were classed as ESBL)
- Staph aureus 22% (of which 44% were MRSA)
- No CRE isolated

PPS of HCAI & antimicrobial use in long term care facilities (HALT) 2013. hpsc

	1 11			1	
Mea	nwhile	⊃ ın	the	bacteria	I World



Lots of resistant bugs around!!



MRSA





Penicillin Resistant Strep pneumonise

delisie alinemia sea di Serata producto gistis







Proportion of Penicillins Resistant (R+I) Streptococcus pneumoniae Isolates in Participating Countries in 2013	
Total Control	
Mill Controlled Contro	
Consequences of antimicrobial resistance	
Treatment failures with empiric antibiotics Increased morbidity/duration of illness Increased mortality Increased healthcare costs Empiric use of broader spectrum antibiotics Further selection of resistance Return to pre-antibiotic era? High mortality from primary infectious diseases Loss of high-tech medicine	
MRSA in Ireland report	
 Prolonged hospital stays increase the chances of acquiring a HAI Patients who acquire a HAI will spend on average an extra 11 days in hospital and these patients are 7 times more likely to die than uninfected patients 	
• Cost of treating HAI annually in Ireland is estimated at €230 million	









Medical consequence of no action

- Previously treatable infections will no longer be so
- Surgical procedures e.g. hip and knee replacement will become too risky to carry out
- Innovations in cancer treatments and radical surgical procedures will no longer be possible due to the risk of untreatable infections in immunocompromised patients

Post antibiotic era?





So what can we do about it

- New antibiotics-20 by 2020
- Antimicrobial stewardship-We all need to make better use of the antibiotic resources we already have





Why has the pipeline of new drugs run dry?

- Scientific difficulties in developing new antibiotics
- Financial and regulatory hurdles
- Lack of incentive
- Patients will only receive short courses
- Once developed specialists will restrict use
- Resistance will eventually develop
- Patent will run out

ARTICLE ##103.000 insensition		
A new antibiotic kills pathogens without		
detectable resistance Inset Lind*, 'Ippi Scholaris'*-, Amor I Pagiele Amer I, Spepring', Ins Tagals'*, Bani F, Cadou's Ama Mardin's', Cana B, 'Sal', 'Analy Fermann', Milliam F, Miller, Analyse G, Mill', Analys K, Ziah', Chan Cane' & Kim Lord's' Cana B, 'Sal', 'Analys Fermann', Milliam F, Miller, 'Analyse G, Mill', Analys K, Ziah', Chan Cane' & Kim Lord's' Analysis and Canada Cane, 'Analysis Cane, 'Analysis and 'Analysis Cane, 'Analysis Can		
handbark redstance is questing later than the introduction of new compounds into this of practice, causing a public based on the compound of the public production of the compound of the comp		
peptidiglycual and lipid III (precursor of cell wall stichtic and). We did not defait any matain of Suphibiorexeas survers of Spoulser from intermediate resistant to technique; and the compound suggest a path sowards developing analysis of the compound suggest a path sowards of resistance.		
II., Nature		
itimicrobial stewardship		
_		
CAVE		
CHANGER		
CHANGER		
tient related factors –major drivers of		
appropriate antimicrobial use		
elf medication		
escribers perceptions regarding patients expectations		
ntient compliance Ospital use of antibiotics		

Inappropriate use and prescribing of antibiotics is causing the development of resistance	
Inappropriate use includes: • not taking your antibiotics as prescribed • skipping doses of antibiotics • not taking antibiotics at regular intervals • saving some for later	
Inappropriate prescribing	
Inappropriate prescribing includes: unnecessary prescription of antibiotics unsuitable use of broad-spectrum antibiotics	
 wrong selection of antibiotics and inappropriate duration or dose of antibiotics 	
Prudent Antimicrobial Use	
 Develop policies and guidelines on the management of infection Support continued professional development Reduce inappropriate antimicrobial prescribing 	
Use clinical governance arrangements to support improved antimicrobial prescribing	
 Identify good prescribing practice Put strategies in place to help optimise concordance 	
Monitor antimicrobial prescribing	



3 things to remember if you are prescribed an antibiotic

- 1. Take them exactly as prescribed.
- 2. Make sure you finish the full course, even if you begin to feel better, to get rid of the bacteria completely.
- 3. Do not 'save' left over antibiotics for the next time you, your child, or any other family member is sick.

Medication prescribed for you now may not be the right medicine for you again or for another person.









EUROPEAN ANTIBIOTIC AWARENESS DAY 18 NOVEMBER ANTIBIOTIC GUARDIAN AND EARD ARE SUPPORTED BY: EUROPEAN ANTIBIOTIC AWARENESS DAY AWARENESS DAY

CHOOSE A PLEDGE AND JOIN THE ANTIBIOTIC GUARDIANS.
RALLY TOGETHER AT <u>ANTIBIOTICGUARDIAN.COM</u>

Basic AMS pro	ogramme
---------------	---------

- Implement and assess compliance with local prescribing guidelines
- Review of indications and durations
- Review of consumption data
- Review of antimicrobial resistance data
- Education and resources



Community Acquired Pneumonia

Treatment in the Community (Adults)

Treatment	Dose	TX Duration
amoxicillin	500 mg - 1g TDS	Up to 10 days
clarithromycin	500 mg BD	Up to 10 days
OR doxycycline	200 mg stat/100 mg OD	Up to 10 days

HALT study

Table 7.6.2 Australia balls accomb of facility accomb and a CN 12-12-1

Antimicrobial name	Number of prescriptions (%)	Antimicrobial name	Number of prescriptions (%)
Treatment for RTI		Prophylaxis against RTI	
Amoxicillin and enzyme inhibitor	57 (43.5)	Amoxicillin and enzyme inhibitor	4 (28.6)
Amoxicillin	23 (17.6)	Azithromycin	3 (21.4)
Clarithromycin	18 (13.7)	Clarithromycin	2 (14.3)
Ciprofloxacin	5 (3.8)	Other	5 (35.7)
Doxycycline	3 (2.3)		
Cefactor	2 (1.5)		
Cefuroxime	2 (1.5)		
Piperacillin and enzyme inhibitor	2 (1.5)		
Cefixime	2 (1.5)		
Erythromycin	2 (1.5)		
Levofloxacin	2 (1.5)		
Other	13 (9.9)		

What to prescribe?



Conclusion

- Antimicrobial resistance is a significant problem facing the world with the very real prospect of a situation where 'the drugs don't work'
- Antimicrobial stewardship is a key element in preserving the effectiveness of the antibiotic resources we already have
- Antimicrobial stewardship is everybody's responsibility

Thank you for your time	
Don't fugget to take a hampful of our complimentary antibiotics on your vary out."	